Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9003
Title: Comparison of CISNE and MASCC Score in Predicting Complications on Post Chemotherapy Febrile Neutropenia
Authors: Shakinah, Sharifah
Nelwan, Erni Juwita
Lubis, Anna Mira
Sinto1, Robert
Lie, Khie Chen
Keywords: CISNE
MASCC score
oncology
infectious disease
Issue Date: Jul-2024
Publisher: Acta Medica Indosiana
Citation: Original Article
Abstract: Background: Febrile neutropenia (FN) is an oncologic emergency which commonly occurrs in patients who undergo chemotherapy, with a mortality rate of 12.5%. Risk stratification in FN plays an important role in increasing the accuracy of therapy. This study aims to compare the performance between CISNE score and MASCC score in predicting complications on post-chemotherapy FN in solid and hematologic malignancy. Methods: This is a retrospective cohort study on FN patients undergoing inpatient treatment at Cipto Mangunkusumo Hospital between July 2015 and December 2019. Basic demographic and clinical data were collected from medical records. Subjects were grouped based on the CISNE and MASCC score, and complications during hospitalization were recorded. Predictive performance of each score was analyzed and compared using area of under curve. Results: CISNE score showed a better performance both in solid malignancy with AUC of CISNE score (0.80 CI 95% 0.73-0.88, p = 0.00) compared to AUC of MASCC score (0.68; 95% CI 0.59 – 0,78, p = 0.00) and in hematologic malignancy with AUC of CISNE score (0.85; 95% CI 0.77 - 0.93, p = 0.00) and AUC MASCC score (0.65 ; 95% CI 0.54 - 0.76, p = 0.007). Conclusion: CISNE score showed a better performance compared to MASCC score in predicting in-hospital complication in both solid and hematologic malignancy with cut-off point of 2.
URI: http://localhost:8080/xmlui/handle/123456789/9003
Appears in Collections:VOL 56 NO 3 2024

Files in This Item:
File Description SizeFormat 
341-348.pdf888.57 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.